UPDATE 1-FDA grants priority review to Chelsea's hypotension drug
November 17, 2011 at 08:31 AM EST
Nov 17 (Reuters) - Chelsea Therapeutics said U.S. health regulators granted a priority review status to its hypotension drug Northera and will review it by next March.
